Almanac A1C

Your 30s: When Aging Silently Steals Muscle Before 60 Hits

Posted

by

A1C Medical Team

Table of Contents
Keywords: , , , ,

Aging Doesn’t Start at 60

Chronological definitions of “older adult” traditionally anchor aging at 60 years and above, shaping eligibility for geriatric services, screening programs and policy thresholds. However, converging epidemiological and biomarker data indicate that biological aging trajectories begin to diverge decades earlier, with meaningful inter-individual differences already detectable in early and mid-adulthood. This reframing challenges the notion of aging as a late-life phenomenon and instead positions it as a progressive, lifelong process with a long subclinical phase in which prevention is both possible and highly impactful.

Large cohort analyses demonstrate that age-related alterations in immune and metabolic biomarkers such as elevations in inflammatory cytokines, vascular adhesion molecules, and pro-thrombotic factors are evident from the third decade of life and track with later functional decline, frailty, and mortality. These findings support the concept of “inflammaging,” in which log-grade, chronic inflammation emerges gradually, preceding overt disease and contributing to the pathogenesis of cardiovascular, metabolic and degenerative conditions. Parallel work in body composition and muscle function shows that handgrip strength and other strength parameters begin a measurable decline form the 30s onward, long before clinical sarcopenia is diagnosed, indicating that musculoskeletal aging also has an early, quantifiable onset.

At the system level, aging thus reflects cumulative, integrating shifts across immune metabolic, and structural domains rather than a discrete transition at a specific birthday. Metabolic studies reveal that while whole-body energy expenditure may remain relatively stable through midlife, changes in body composition including gradual loss of muscle mass and redistribution of fat toward central depots are already underway and linked to adverse risk profiles. Recognizing aging as a continuum beginning in the 30s, with measurable biomarker and body-composition changes, underscores the need to bring geroscience principles into earlier life stages and to reposition midlife as a critical window for interventions aimed at extending health span, not merely delaying end-stage disease.

The Silent Shift: Hormones, Muscle, and Fat in Your 30s

Endocrine aging in the 30s and 40s is characterized by a gradual, multi-axis shift rather than an abrupt failure of any single hormone system, and these changes frequently precede overt abnormalities on standard laboratory testing. The GH/IGF-1 axis shows a progressive decline in pulsatile GH secretion and circulating IGF-1 from early adulthood onward, with estimates suggesting a fall in GH output of roughly 10-15% per decade, accompanied by reductions in pulse amplitude and frequency. This decline is mechanistically linked to decreased muscle protein synthesis, reduced satellite cell activation, and diminished capacity for muscle repair, while simultaneously favouring increased total and trunk fat mass and adverse lipid profiles. Clinical and interventional data indicate that adults with GH deficiency, whether pathological or age-related, exhibit reduced lean mass, increased visceral adiposity, and lower exercise capacity, and that GH replacement can partially reverse these body-composition abnormalities, underscoring the central role of this axis in maintaining youthful muscle and fat distribution [1,2,3,4,5,6,7].

Sex steroid trajectories in the 30s-40s further compound these trends. In women, early endocrine aging involves both quantitative and qualitative changes in ovarian function: progresterone levels often decline first with more anovulatory cycles, while estradiol becomes increasingly erratic in the late 30s and 40s, sometimes reaching supraphysiologic peaks during perimenopause before ultimately falling. These fluctuations are associated with worsening premenstrual symptoms, sleep disturbance, mood variability, and a shift in fat deposition from gluteofemoral to central stores, alongside a gradual reduction in muscle mass and strength. In men, total and free testosterone decline slowly from early midlife at an average of about 1% per year, with substantial inter-individual variability; even within “normal” reference intervals, lower testosterone levels correlate with reduced muscle mass, hight fat mass (particularly visceral), decreased libido, and fatigue, observational and interventional trials in hypogonadal men consistently demonstrate that androgen replacement increases lean body mass and decreases fat mass suggesting that the modest cumulative declines seen in eugonadal men across the 30s and 40s likely contribute meaningfully to early shifts in body composition and energy [4,5,6,7,8,9].

Thyroid and adrenal dynamics modulate how these hormonal changes are experienced subjectively. Subtle alterations in thyroid axis activity, such as upward drift of TSH within the reference range or minor reductions in free T4 and T3 have been associated with fatigue, weight gain, cold intolerance, cognitive slowing, and myalgias, even when laboratory values remain technically “normal” by population standards. Similarly, chronic psychosocial stress and sleep curtailment, which are common in the 30s and 40s, can lead to sustained elevations in cortisol and blunting of nocturnal GH peaks, further promoting central adiposity, impairing muscle recovery, and worsening subjective tiredness. Emerging work on age- and sex-specific reference intervals underscores that using broad adult ranges may obscure functionally relevant deviations in midlife, such that individuals experiencing clinically meaningful endocrine aging are often reassured that “everything is normal” on blood tests [4,10,11,12].

The clinical picture described in the social media narrative, subtle but progressive muscle loss, creeping fatigue, and disproportionate weight gain centered in the abdomen is therefore highly congruent with the physiology of early endocrine aging, longitudinal an cross-sectional studies show that skeletal muscle mass and strength begin to decline measurably from the fourth decade, with losses in lean mass on the order of a few percent per decade and earlier, steeper declines in strength, while fat mass and particularly visceral adipose tissue gradually rise. These compositional shifts often occur without major changes in body weight, making them easy to miss clinically and leading patients to attribute symptoms to “being busy” or “just getting older,” even though they reflect an unfavourable rebalancing between metabolically active muscle and metabolically harmful fat. When viewed through a geroscience lens, this combination of hormonal drift, early sarcopenic change, and central fat accumulation in the 30s and 40s functions as an early-warning phenotype of accelerated biological aging, one that precedes overt frailty, diabetes, or cardiovascular disease by years and therefore represents a critical, under-recognized window for preventive intervention [1,13,14,15,16,17].

Muscle Loss as The First Visible Aging Phenotype

Skeletal muscle reaches its maximal quantity and functional capacity in early adulthood, typically around the third decade of life, after which an involuntary and progressive decline in mass and strength becomes apparent. Longitudinal and cross-sectional data suggest that, in the absence of regular resistance training, muscle mass decreases by approximately 3-8% per decade beginning after age 30, with the rate of decline accelerating beyond the age of 60. Muscle strength often falls even more steeply than mass, with some studies showing strength losses of 16-40% when comparing adults under 40 with those over 40, and a curvilinear pattern in which declines in handgrip strength and functional tests such as chair stands become measurable from the 30s-40s onwards. Histological and molecular analyses indicate that these changes reflect a combination of type II fiber atrophy, motor unit denervation, impaired neuromuscular junction integrity, and reduced regenerative capacity, collectively defining the early stages of sarcopenia well before overt disability of frailty emerge [16,18,19,20,21,22].

Clinically, early sarcopenia is rarely recognized as an aging phenotype because it is masked by stable or increasing body weight, leading both patients and clinicians to focus on fat gain while overlooking declining lean mass. Population studies demonstrate that many adults in midlife expedience “body composition crossover” in which muscle mass and strength begin to fall at the same time as total and visceral fat gradually rise, producing little net change on the scale but a marked deterioration in metabolic and functional reserves. Thie pattern underpins the phenotype of sarcopenic obesity, in which reduced muscle mass and strength coexist with excess adiposity and are associated with higher risk of multimorbidity, falls, fractures, disability, and all-cause mortality than either sarcopenia or obesity alone. Because standard clinical encounters still rely heavily on body mass index (BMI) and weight trends rather than direct assessment of muscle mass and strength, early sarcopenia is frequently misinterpreted as “normal midlife weight gain” or a nonspecific “slow metabolism,” rather than as a discrete, modifiable process of muscular aging that warrants targeted intervention [20,23,24,25,26].

Symptomatically, the first manifestations of this muscle decline often align with patient narratives of “feeling older” in the 30s and 40s: reduced stamina for previously well-tolerated activities, heavier limbs when climbing stairs, and difficulty maintaining posture or joint stability after prolonged sitting or screen time. These complaints are easily attributed to stress, parenting demands, or sedentary work, and are seldom connected to underlying structural changes in skeletal muscle and neuromuscular function. However, normative datasets mapping muscle health metrics show that handgrip strength, chair stand performance, and gait speed begin to deviate from young-adult reference values already in midlife, indicating that the “first visible ging phenotype” for many individuals is not wrinkles or gray hair but declining muscle capacity. Recognizing muscle loss as an early as an early, central component of biological aging reframes these symptoms and subtle functional changes as early-warning signs with a clear therapeutic target such as progressive resistance training, adequate protein intake, and lifestyle strategies to slow or partially reverse the trajectory of sarcopenia rather than accepting it as an inevitable consequence of getting older [16,19,20,21,22,24,27].

Sarcopenia, Metabolism, and Midlife Health

Skeletal muscle is the largest organ in non-obese individuals and functions as the predominant site of insulin-stimulated glucose uptake, accounting for approximately 70-80% of whole body glucose disposal from an oral or intravenous load under hyperinsulinemic‑euglycemic clamp conditions. This central role in glucose homeostasis underscores why even modest declines in muscle mass and insulin sensitivity during midlife have systemic metabolic consequences. In addition to its capacity for glucose clearance, skeletal muscle mass is a major determinant of resting energy expenditure (REE), with estimates suggesting that REE falls by approximately 418 kJ per day for every 10 kg of lean mass lost, potentially translating to nearly 5 kg of fat gain per year if energy intake remains unchanged. Thus, early sarcopenia not only reduces functional capacity but also shifts the body’s metabolic “set point” toward reduced energy expenditure, positive energy balance, and progressive fat accumulation, particularly in the visceral compartment [28,29,30,31,32,33,34,35].

Beyond its role as a passive metabolic sink, muscle is now recognized as an endocrine organ that secretes bioactive proteins termed myokines in response to contraction and metabolic stress. Myokines such as interleukin-6 (IL-6) and irisin mediate inter-organ crosstalk, influencing adipose tissue lipolysis, hepatic glucose production, pancreatic insulin secretion, and adipocyte “browning,” while also exerting anti-inflammatory and insulin-sensitizing effects systemically. Exercise- induced increases in IL-6 and irisin have been linked to reductions in visceral adipose tissue, improvements in whole-body body tolerance, and attenuation of chronic low-grade inflammation in both healthy and metabolically compromised adults. Conversely, when muscle mass declines and contractile activity is reduced as it occurs with early sarcopenia and sedentary behaviour, myokine secretion is blunted, adipokine dysregulation becomes more pronounces (e.g., elevated leptin, reduced adiponectin), and the balance shift toward a pro-inflammatory, insulin-resistant, and adipogenic state [36,37,38,39,40,41,42,43,44].

Longitudinal and cross-sectional studies consistently demonstrate that midlife muscle decline is independently associated with development of insulin resistance, accumulation of visceral adipose tissue, and increased risk of cardiometabolic disease over subsequent decades. Sarcopenic obesity, defined by the coexistence of low muscle mass and excess adiposity, is associated with synergistic increases in metabolic syndrome, type 2 diabetes, cardiovascular events, and all‑cause mortality, with effect sizes substantially exceeding those of either sarcopenia or obesity alone. Visceral adiposity, in particular, functions as a metabolically harmful depot, secreting pro‑inflammatory cytokines and free fatty acids that promote systemic insulin resistance, hepatic steatosis, dyslipidemia, and endothelial dysfunction, while simultaneously impairing the anabolic and insulin‑sensitizing effects of residual muscle mass. Mechanistic work indicates that insulin resistance in muscle disrupts protein balance reducing synthesis via PI3K‑Akt‑mTOR pathways while increasing degradation through ubiquitin‑proteasome and autophagy‑lysosomal systems, thereby establishing a feed‑forward loop in which declining muscle accelerates insulin resistance, fat gain, and further muscle loss. Recognizing this bidirectional relationship positions early sarcopenia not simply as a consequence of aging or inactivity, but as a central, modifiable driver of metabolic aging, and a critical therapeutic target for preventing the cardiometabolic disease burden that emerges clinically in the fifth, sixth, and seventh decades of life [13,45,46,47,48,49,50].

Why You Feel “Older” Overnight: Bursts and Trajectories

The public narrative of “suddenly feeling older”, waking up one day to find that alcohol hangovers are more brutal, recovery from workouts takes longer, or body fat has inexplicably migrated to the abdomen has long been dismissed as anecdotal or attributed to lifestyle alone. However, recent multi‑omics research tracking thousands of proteins, metabolites, microbes, and RNA transcripts across the adult lifespan has revealed that aging is not a gradual, linear process but instead unfolds in nonlinear waves with two major inflection points, occurring around ages 44 and 60. These findings are derived from dense longitudinal and cross‑sectional molecular profiling of over 100 participants aged 25 to 75, with validation across independent datasets totaling more than 19,000 individuals, and they demonstrate that approximately 81% of measured molecules exhibit non‑linear fluctuations rather than steady age‑related drift. At these transition points, thousands of distinct molecular species undergo rapid and coordinated changes in abundance, corresponding to shifts in immune regulation, carbohydrate and lipid metabolism, cardiovascular function, kidney performance, and skin and muscle integrity [51,52,53,54,55,56,57].

The mid-40s spike, often surprising because it predates menopause in women and was initially hypothesized to reflect female‑specific hormonal changes affects men and women equally and is characterized by dysregulation in pathways related to alcohol metabolism, caffeine processing, lipid handling, and cardiovascular health, as well as markers of skin and muscle aging. Complementary brain‑aging studies using functional MRI data have shown that brain network instability also follows a nonlinear trajectory, with a critical transition beginning in the 40s and linked to metabolic changes, particularly insulin resistance, suggesting that midlife is a period in which neurometabolic and systemic aging accelerates in parallel. The 60‑year transition, by contrast, is marked by steep changes in immune function, carbohydrate metabolism, kidney markers, and oxidative stress, aligning with well‑documented epidemiologic spikes in cardiometabolic and neurodegenerative disease risk in the seventh decade. Pathway enrichment analyses reveal that DNA repair capacity, autophagy, and mitochondrial function exhibit complex nonlinear patterns, often peaking in early midlife and then declining sharply between ages 50 and 60, providing a mechanistic rationale for the subjective experience of an aging “cliff” [51,52,54,55,57,58].

Critically, these stepwise molecular accelerations do not appear suddenly without antecedents; instead, they reflect the cumulative outcome of decades of subclinical drift that began much earlier. Hormonal changes in the 30s, including gradual declines in GH/IGF-1, sex steroids, and thyroid axis activity along with early losses in muscle mass and strength and increases in visceral adiposity, establish a vulnerability landscape that is then “unmasked” when the biological system reaches a tipping point in the 40s. In women, perimenopause typically begins in the late 30s to early 40s, with erratic estrogen and declining progesterone causing a cascade of changes in fat distribution, insulin sensitivity, sleep, mood, and muscle recovery years before the final menstrual period. Many perimenopausal symptoms such as weight gain, fatigue, joint pain, and brain fog are often mistaken for stress, aging, or poor lifestyle, but they in fact signal underlying neuroendocrine and metabolic reprogramming. In men, similar midlife changes occur, driven by androgen decline and metabolic shifts that are molecularly detectable but clinically silent until functional reserves are exhausted. The “sudden” symptoms people notice in their 40s and 50s are therefore not the beginning of aging, but rather the symptomatic manifestation of years of quiet hormonal, muscular, and metabolic erosion, which, upon crossing a threshold, produces rapid, perceptible deterioration in energy, body composition, and resilience [51,52,54,55,57,58].

Detection in the Decades That Matter: 30s and 40s

Symptom-based recognition of aging—patients in their 30s and 40s describing themselves as “tired, soft, and heavier around the middle” despite “normal” laboratory tests misses a long subclinical window in which muscle mass, strength, and physical performance are already declining. Consensus groups now advocate shifting from this passive, symptom-driven model to proactive, structured screening of muscle quantity and function in apparently healthy adults, especially those with sedentary lifestyles, central adiposity, or family histories of cardiometabolic disease. The updated European Working Group on Sarcopenia in Older People (EWGSOP2) framework emphasizes low muscle strength as the primary criterion for “probable sarcopenia,” to be confirmed by measures of muscle mass and further staged by physical performance, and although originally designed for older adults, its logic is directly applicable to midlife screening [16,35,59,60,61,62].

Handgrip strength, five‑time chair‑stand performance, and usual gait speed offer simple, low‑cost entry points for detecting early compromise in muscle function before overt disability develops. Handgrip strength is strongly associated with all‑cause and cardiovascular mortality, frailty, and hospitalization risk, and cut‑points proposed by EWGSOP2 and other groups help identify individuals with weakness who may benefit from targeted intervention. The five‑time chair‑stand test, typically considered prolonged when it exceeds 15 seconds, is a practical proxy for lower‑limb strength and power and may be more sensitive than grip strength in individuals with higher adiposity or lower‑body deconditioning, capturing “low relative strength” that would be missed by upper‑limb measures alone. Usual gait speed over 4–6 meters (with thresholds such as <0.8 m/s indicating slowness) integrates multiple domains which are strength, balance neuromotor control, and cardiopulmonary capacity and has been suggested by some panels as an equal or even superior predictor of adverse outcomes compared with composite sarcopenia definitions [16,59,63,64,65,66,67].

Beyond clinic-based tests, everyday digital metrics such as step counts provide a scalable lens on functional aging in midlife. Large cohort studies of middle‑aged adults demonstrate that accumulating at least 7000–8000 steps per day is associated with approximately 50–70% lower all‑cause mortality compared with taking fewer than 4000–7000 steps per day, with little additional mortality benefit above 10,000–12,000 steps. These findings support the integration of wearables and smartphone‑based step tracking into routine preventive care, not merely as lifestyle coaching tools but as longitudinal biomarkers of mobility and cardiometabolic risk. For adults in their 30s and 40s, combining step‑count trajectories with periodic assessments of grip strength, chair‑stand time, and gait speed can reveal early functional decline even when self‑reported activity levels seem adequate [16,65,68,69,70].

Body‑composition assessment adds another critical dimension, helping distinguish benign weight stability from unfavourable shifts toward sarcopenic obesity. Dual‑energy X‑ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), and emerging imaging‑based estimates of visceral adipose tissue allow clinicians to quantify appendicular lean mass, fat distribution, and skeletal muscle index, which have been linked to incident disability, cardiometabolic disease, and mortality. Studies show that midlife adults can lose several kilograms of muscle while gaining visceral fat with little net change in body weight, underscoring the limitations of BMI‑only surveillance. Incorporating periodic body‑composition measurements into preventive check‑ups for at‑risk 30‑ and 40‑year‑olds, particularly those with rapid waist‑circumference gain, family history of diabetes, or subjective decline in strength, enables  earlier identification of deleterious trajectories and more targeted counselling [13,24,29,34,61].

Finally, simple hormone and metabolic panels can be used as adjunctive tools to flag early risk states that synergize with muscle decline. Fasting glucose, HbA1c, and lipid profiles remain foundational, but adding fasting insulin or indices such as HOMA‑IR improves detection of early insulin resistance, which is strongly associated with central adiposity, low sex hormone–binding globulin, and emerging sarcopenic obesity in midlife. Basic endocrine markers, including TSH and free thyroid hormones, sex steroids (estradiol or testosterone), and, where indicated, markers of liver fat or inflammatory burden can contextualize clinical complaints of fatigue, weight redistribution, and reduced exercise tolerance, particularly in perimenopausal women and men with features of functional hypogonadism. When these biochemical data are interpreted alongside objective measures of strength, performance, step counts, and body composition, the narrative shifts from “I’m just tired and soft” to a quantifiable picture of early musculoskeletal and metabolic aging, opening the door to structured interventions in the decades that matter most for long‑term health span [1,71,72].

Intervening Early: Lifting, Protein, and Lifestyle “Hormone Support”

Offsetting age-related muscle loss in the 3–8% per decade range after age 30 requires moving from generic “stay active” advice to structured, progressive resistance training protocols that are anchored in evidence. Position statements and meta-analyses indicate that at least two, and preferably three, weekly resistance sessions involving major muscle groups, performed at moderate to high intensity (roughly 60–80% of one‑repetition maximum) with 1–3 sets of 8–12 repetitions, can meaningfully increase or maintain muscle mass and strength in older adults and are likely even more effective when initiated in midlife. Progressive overload, systematically increasing load, volume, or complexity as strength improves is critical to counteract anabolic resistance and maintain hypertrophic stimuli across the lifespan, and can be operationalized in practice through simple rules such as adding weight once a person can perform more than 12 repetitions with good technique, or gradually increasing total weekly sets for each muscle group. Complementary targets such as accumulating 7000–10,000 steps per day and breaking up sedentary time with brief walking or mobility “snacks” help sustain cardiorespiratory fitness and metabolic flexibility, but without dedicated loading of skeletal muscle they are insufficient to prevent sarcopenia [18,68,73,74,75,76,77,78].

Nutritional strategies must match this mechanical stimulus to fully realize gains in muscle and metabolic health. Emerging consensus suggests that the Recommended Dietary Allowance of 0.8 g/kg/day protein is inadequate for preserving muscle in aging populations, with multiple reviews and indicator amino acid oxidation studies supporting daily intakes in the range of 1.0–1.2 g/kg for healthy older adults and up to 1.2–1.5 g/kg or higher in those with sarcopenia, illness, or high training loads, adjusted for renal function. Distributing protein evenly across meals (approximately 25–30 g of high‑quality protein per eating occasion) appears to optimize muscle protein synthesis, particularly in the context of anabolic resistance, and is consistent with practical “per meal” guidance often highlighted in social‑media education. Adequate dietary fiber (from vegetables, fruits, whole grains, and legumes) supports glycemic control, satiety, and gut‑derived metabolites that may influence muscle and bone metabolism, while micronutrients such as vitamin D, calcium, and B vitamins play established roles in muscle function, neuromuscular coordination, and energy metabolism. Sleep and stress regulation further act as “hormone support” levers: deep sleep is a primary window for pulsatile growth hormone release and nocturnal testosterone surges, whereas chronic sleep restriction and stress‑driven hypercortisolemia impair muscle recovery, promote central fat gain, and blunt training adaptations, effectively accelerating the very aging processes patients seek to avoid. Taken together, an integrated program of progressive resistance training, adequate daily movement, protein‑optimized and nutrient‑dense nutrition, and deliberate protection of sleep and stress physiology offers a mechanistically grounded translation of social‑media advice into protocols that can realistically offset, and in some cases partially reverse, age‑related losses in muscle mass, strength, and energy after the age of 30 [73,76,70,8-,81].

Women, Menopause, and the Second Wave of Muscle Aging

Perimenopause and menopause represent a second, distinct wave of musculoskeletal and metabolic aging that amplifies the quieter changes already underway in women’s 30s. As ovarian estrogen production declines and cycles become irregular, longitudinal and cross‑sectional studies show a characteristic shift in body composition: total fat mass increases, fat redistributes from gluteofemoral to central depots, visceral adipose tissue accumulates, and lean mass and muscle strength decline at an accelerated rate compared with premenopausal peers. Estrogen deficiency promotes visceral fat gain via changes in adipocyte biology and energy partitioning, and is associated with higher levels of pro‑inflammatory cytokines such as TNF‑α and IL‑6, which further contribute to loss of muscle mass, reduced muscle power, and higher prevalence of sarcopenia in postmenopausal women. Epidemiologic data suggest that after menopause, muscle mass can decline by roughly 0.5–0.6% per year, and that a substantial proportion of peri‑ and postmenopausal women already meet criteria for low skeletal muscle mass and high visceral fat despite relatively modest changes in body weight [82,83,84,85,86,87,88].

Against this backdrop, the idea that women in their 20s and 30s should “train for their future hormones” has a strong physiological rationale. Peak bone and muscle mass are typically achieved by the late 20s to early 30s, and randomized trials in premenopausal women show that 12–18 months of resistance and impact training can increase lean soft tissue, regional bone mineral density, and muscular strength by 30–60%, improvements that effectively raise the starting point from which age- and menopause‑related declines occur. Observational and interventional work indicates that women who enter the menopause transition with higher appendicular lean mass, better muscle power, and established strength‑training habits experience less severe declines in muscle and bone, fewer functional limitations, and a lower burden of sarcopenic obesity and metabolic complications later in life. In practical terms, this means that resistance and power training, adequate protein and micronutrient intake, and lifestyle factors that support endocrine health before estrogen begins to fall are not merely “fitness” recommendations, but a strategy to build structural and metabolic reserve that can buffer the second wave of muscle aging associated with menopause [83,84,87,89,90,91,92,93].

AI and Data: Turning a Viral Message into a Clinical Pathway

Digital phenotyping offers a way to transform a viral message about “quiet aging” in the 30s into a structured clinical pathway by continuously capturing the very patterns highlighted in the post—fatigue, reduced movement, muscle loss, and fat gain, in real time. Wearables and smartphones can passively collect step counts, gait characteristics, heart rate variability, sleep duration and fragmentation, and even dual‑task gait metrics that have emerged as potential digital biomarkers of sarcopenia and frailty. Machine‑learning and deep‑learning models can then integrate these signals with electronic health record data (age, comorbidities, medications) and simple clinic measures (grip strength, chair stand, BMI/waist circumference) to classify probable sarcopenia or sarcopenic obesity and to flag individuals whose activity patterns, gait features, or recovery curves deviate from expected trajectories for their age and sex. Early work shows that AI models can detect sarcopenia from gait sequences, foot‑pressure maps, surface EMG, or imaging‑derived muscle volumes with high accuracy, supporting the feasibility of embedding such algorithms into routine musculoskeletal and primary‑care workflows [94,95,96,97,98,99,100,101].

Beyond detection, integrating continuous glucose monitoring (CGM), physical‑activity data, body‑composition measurements, and hormone/metabolic markers enables genuinely personalized prevention programs for sarcopenia and metabolic aging beginning in the 30s. CGM data reveal individual glycemic responses to meals and exercise, helping tailor nutrition and training to reduce glycemic variability, preserve lean mass, and limit visceral fat gain, even in people without diabetes. Periodic DXA or BIA scans provide quantitative trajectories of appendicular lean mass and visceral adiposity, while basic panels (fasting glucose/insulin or HOMA‑IR, lipids, liver fat surrogates, and simple sex‑hormone/thyroid markers) contextualize digital signals in terms of endocrine and metabolic risk. AI models can learn from these multimodal inputs to generate individualized risk scores and recommendations, for example, adjusting resistance‑training volume, daily step targets, protein intake, and sleep goals to maintain muscle, curb visceral adiposity, and slow biological aging, operationalizing a social‑media quote into a continuous, data‑driven, midlife prevention pathway [13,29,71,94,102,103].

Public Communication: Bridging Instagram and Evidence-Based Care

High-engagement Instagram posts that state that aging “starts in your 30s” and depict visible muscle loss function as a bridge between lay perceptions of aging and evidence-based concepts of early sarcopenia, metabolic decline, and midlife screening, provided they are anchored in accurate physiology and clear calls to action. Health communication studies suggest that social media can substantially increase exposure to preventive messages and shape norms around movement, muscle, and screening, but also that users judge credibility by aesthetics and relatability, which makes concise, visually “sticky” phrases and narratives particularly powerful for reframing when aging begins and why muscle mass matters for long-term metabolic health and quality of life. At the same time, fear-heavy or purely loss-framed content, emphasizing “deterioration,” “sudden aging,” or “muscle loss” without efficacy-focused guidance can raise anxiety, amplify misinformation, and drive people toward quick fixes or supplements marketed by influencers rather than structured programs of resistance training, nutritional optimization, and early clinical assessment. Meta-analytic data on message framing indicate that loss-framed messages can acutely increase intentions for detection behaviours such as cancer screening, whereas gain-framed messages may be more effective for sustaining preventive behaviours, underscoring the need to pair any fear-evoking hook with simple, concrete pathways to evidence-based actions (e.g., muscle-strength testing, step-count goals, progressive resistance training, and age-appropriate metabolic panels) rather than vague warnings or product-centric solutions. In this context, Instagram can be leveraged as a public communication channel where emotionally engaging, concise statements about early aging are deliberately coupled with empowering, gain-framed invitations to early screening and structured prevention, thereby translating attention into informed, clinically aligned behaviour rather than into anxiety, fatalism, or unregulated supplement use [104,105,106,107,108,109].

Your 30s as the Lifespan “Fork in the Road”

The third decade of life represents a pivotal inflection point in the trajectory of human health and longevity. Rather than signalling the onset of decline, the 30s mark the transition from biological plasticity to physiological consolidation, when small shifts in muscle mass, metabolic efficiency, and behavioural patterns begin to set the stage for midlife and beyond. This period defines whether cellular resilience and functional capacity are maintained or gradually eroded. Viewed through this lens, the 30s are not the beginning of the end, but the decisive decade when investment in strength, movement and metabolic regulation determines how robustly one will age into the 60s and beyond.

A new paradigm of preventive care is urgently needed, one that aligns clinical practice, artificial intelligence, driven insight, and public education to anticipate rather than react to age-related decline. Such a framework would move beyond episodic screening and instead stratify risk and tailor interventions dynamically across this formative decade. Empowered by continuous health data and evidence-based guidance, individuals could view “aging starts in your 30s” not as a prognosis to fear but as a powerful prompt for early action. In reframing this narrative, health system can shift the culture around aging, from passive expectation to proactive mastery, transforming the 30s into the decade that preserves vitality rather than concedes it

Reference

  1. Gupta P, Kumar S. Sarcopenia and Endocrine Ageing: Are They Related? Cureus. 2022 Sep 5;14(9).
  2. Rolland Y, Czerwinski S, van Kan GA, Morley JE, Cesari M, Onder G, et al. Sarcopenia: Its assessment, etiology, pathogenesis, consequences and future perspectives. The Journal of Nutrition Health and Aging. 2008 Sep;12(7):433–50.
  3. Feldt-Rasmussen U, Klose M. Adult Growth Hormone Deficiency Clinical Management [Internet]. Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, et al., editors. PubMed. South Dartmouth (MA): MDText.com, Inc.; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK425701/
  4. Coggins C, Patel S, Nigam S, Rai V. Hormonal changes during aging and their effects on quality of life. Exploration of Endocrine and Metabolic Diseases. 2025 Nov 10;2
  5. Huang X, Blackman MR, Herreman K, Pabst KM, Harman SM, Caballero B. Effects of growth hormone and/or sex steroid administration on whole-body protein turnover in healthy aged women and men. Metabolism. 2005 Sep;54(9):1162–7.
  6. Fernández-Garza LE, Guillen-Silva F, Sotelo-Ibarra MA, Andrés Ely Domínguez-Mendoza, Barrera-Barrera SA, Barrera-Saldaña HA. Growth hormone and aging: a clinical review. Frontiers in Aging. 2025 Apr 7;6.
  7. Growth Hormone Deficiency in Adults: Background, Etiology, Epidemiology. eMedicine [Internet]. 2022 Jun 17; Available from: https://emedicine.medscape.com/article/120767-overview
  8. Hurtado MD, Saadedine M, Kapoor E, Shufelt CL, Faubion SS. Weight Gain in Midlife Women. Current obesity reports. 2024 Feb 28;
  9. How Thyroid Disease in Men Differ From Women [Internet]. Verywell Health. Available from: https://www.verywellhealth.com/thyroid-disease-in-men-3886166
  10. Twin Cities Integrative Medicine. Thyroid Problems in Your 30s and 40s – Twin Cities Integrative Medicine [Internet]. Twin Cities Integrative Medicine. 2023. Available from: https://tcintmed.com/thyroid-problems-in-your-30s-and-40s/
  11. Yamada S, Kazuhiko Horiguchi, Akuzawa M, Koji Sakamaki, Yamada E, Ozawa A, et al. The Impact of Age- and Sex-Specific Reference Ranges for Serum Thyrotropin and Free Thyroxine on the Diagnosis of Subclinical Thyroid Dysfunction: A Multicenter Study from Japan. Thyroid. 2023 Apr 1;33(4):428–39.
  12. Hypothyroidism in Women: 10 Signs and Symptoms to Know – GoodRx [Internet]. GoodRx. Available from: https://www.goodrx.com/conditions/hypothyroidism/hypothyroidism-in-women-signs-and-symptoms
  13. Chen Y, Wu J. Aging-Related Sarcopenia: Metabolic Characteristics and Therapeutic Strategies. Aging and disease. 2024;0.
  14. Palmer AK, Jensen MD. Metabolic changes in aging humans: current evidence and therapeutic strategies. Journal of Clinical Investigation [Internet]. 2022;132(16). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374375/
  15. Trombetti A, Reid KF, Hars M, Herrmann FR, Pasha E, Phillips EM, et al. Age-associated declines in muscle mass, strength, power, and physical performance: impact on fear of falling and quality of life. Osteoporosis International. 2015 Jul 21;27(2):463–71.
  16. Beenakker KGM, Ling CH, Meskers CGM, de Craen AJM, Stijnen T, Westendorp RGJ, et al. Patterns of muscle strength loss with age in the general population and patients with a chronic inflammatory state. Ageing Research Reviews [Internet]. 2010 Oct [cited 2019 Nov 25];9(4):431–6. Available from: https://www.sciencedirect.com/science/article/pii/S1568163710000486
  17. ALLA ZAENTC | FUNCTIONAL AND LONGEVITY MEDICINE SPECIALIST on Instagram: “Aging doesn’t begin at 60 — it starts in your 30s. Hormones silently change long before symptoms appear. Muscle loss, fatigue, fat gain, poor sleep — none of this is random. The key is early awareness, proper testing, and smart intervention. Not guesswork. Not trends. Science. #HormonesAfter30 #HealthyAging #LongevityScience #Biohacking #HormoneHealth #MuscleHealth #MetabolicHealth #AntiAgingMedicine #FunctionalMedicine #StressHormones #SleepAndRecovery #WomenAndMenHealth #hormones #peptides # longevity #wellness #uaelife #dubailife” [Internet]. Instagram. 2017 [cited 2026 Jan 5]. Available from: https://www.instagram.com/p/DSqI-JykyLd/
  18. Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Current opinion in clinical nutrition and metabolic care [Internet]. 2004;7(4):405–10. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2804956/
  19. Wiedmer P, Jung T, Castro JP, Pomatto LCD, Sun PY, Davies KJA, et al. Sarcopenia – Molecular mechanisms and open questions. Ageing Research Reviews [Internet]. 2021 Jan;65:101200. Available from: https://www.sciencedirect.com/science/article/pii/S1568163720303354
  20. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia. Journal of the American Medical Directors Association [Internet]. 2011 May;12(4):249–56. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377163/
  21. Keller K, Engelhardt M. Strength and muscle mass loss with aging process. Age and strength loss. Muscles, Ligaments and Tendons Journal [Internet]. 2014 Feb 24;3(4):346. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3940510/
  22. Chen L, Meng L, Peng L, Lee W, Zhang S, Nishita Y, et al. Mapping Normative Muscle Health Metrics Across the Aging Continuum: A Multinational Study Pooling Data From Eight Cohorts in Japan, Malaysia and Taiwan. Journal of Cachexia, Sarcopenia and Muscle. 2025 Feb;16(1).
  23. Axelrod CL, Wagner Silva Dantas, Kirwan JP. Sarcopenic obesity: emerging mechanisms and therapeutic potential. Metabolism-clinical and Experimental. 2023 Sep 1;146:155639–9
  24. Cleveland Clinic. Sarcopenia (Muscle Loss): Symptoms & Causes [Internet]. Cleveland Clinic. 2022. Available from: https://my.clevelandclinic.org/health/diseases/23167-sarcopenia
  25. Benz E, Pinel A, Guillet C, Capel F, Pereira B, De Antonio M, et al. Sarcopenia and Sarcopenic Obesity and Mortality Among Older People. JAMA Network Open [Internet]. 2024 Mar 25;7(3):e243604. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2816734
  26. Cheng G, Zhou Y, Wang Y, Wang C, Xu J. The relationship between early adulthood obesity and sarcopenic obesity among middle-aged and older adults in the United States. Frontiers in Public Health [Internet]. 2025 Sep 1 [cited 2026 Jan 5];13. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12433845/
  27. Wilkinson DJ, Piasecki M, Atherton PJ. The age-related loss of skeletal muscle mass and function: Measurement and physiology of muscle fibre atrophy and muscle fibre loss in humans. Ageing Research Reviews [Internet]. 2018 Nov;47:123–32. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202460/
  28. Merz KE, Thurmond DC. Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake. Comprehensive Physiology [Internet]. 2020 Jul 8;10(3):785–809. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8074531/
  29. Welch AA, Hayhoe RPG, Cameron D. The relationships between sarcopenic skeletal muscle loss during ageing and macronutrient metabolism, obesity and onset of diabetes. Proceedings of the Nutrition Society. 2019 Nov 5;79(1):158–69.
  30. Islam H, Gillen JB. Skeletal muscle mechanisms contributing to improved glycemic control following intense interval exercise and training. Sports Medicine and Health Science [Internet]. 2023 Jan 25; Available from: https://www.sciencedirect.com/science/article/pii/S2666337623000021
  31. DeFronzo RA, Tripathy D. Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes. Diabetes Care. 2009 Oct 29;32(suppl_2):S157–63.
  32. Sjøberg KA, Frøsig C, Kjøbsted R, Sylow L, Kleinert M, Betik AC, et al. Exercise Increases Human Skeletal Muscle Insulin Sensitivity via Coordinated Increases in Microvascular Perfusion and Molecular Signaling. Diabetes. 2017 Mar 14;66(6):1501–10.
  33. Ding H, Zhang L, Ma C, Shao Z, Zhao X, Li C. Association between basal metabolic rate and cognitive function in Chinese older adults: the mediating effect of sarcopenia. BMC Geriatrics [Internet]. 2025 Aug 16 [cited 2026 Jan 5];25(1). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12357453/
  34. Cho YJ, Lim YH, Yun JM, Yoon HJ, Park M. Sex- and age-specific effects of energy intake and physical activity on sarcopenia. Scientific Reports. 2020 Jun 17;10(1).
  35. Wilson MMG, Morley JE. Invited Review: Aging and energy balance. Journal of Applied Physiology. 2003 Oct;95(4):1728–36.
  36. Ciudin A, Simó-Servat A, Palmas F, Barahona MJ. Sarcopenic obesity: A new challenge in the clinical practice. Endocrinología, Diabetes y Nutrición (English ed). 2020 Dec;67(10):672–81.
  37. Maalouf GE, El Khoury D. Exercise-Induced Irisin, the Fat Browning Myokine, as a Potential Anticancer Agent. Journal of Obesity. 2019 Apr 1;2019:1–8.
  38. Severinsen MCK, Pedersen BK. Muscle–Organ Crosstalk: The Emerging Roles of Myokines. Endocrine Reviews. 2020 May 11;41(4):594–609.
  39. Hoffmann C, Weigert C. Skeletal Muscle as an Endocrine Organ: The Role of Myokines in Exercise Adaptations. Cold Spring Harbor Perspectives in Medicine. 2017 Apr 7;7(11):a029793.
  40. Laurens C, Bergouignan A, Moro C. Exercise-Released Myokines in the Control of Energy Metabolism. Frontiers in Physiology. 2020 Feb 13;11.
  41. Iglesias P. Muscle in Endocrinology: From Skeletal Muscle Hormone Regulation to Myokine Secretion and Its Implications in Endocrine–Metabolic Diseases. Journal of Clinical Medicine [Internet]. 2025 Jun 25 [cited 2025 Aug 5];14(13):4490–0. Available from: https://www.mdpi.com/2077-0383/14/13/4490
  42. Ahima RS, Park HK. Connecting Myokines and Metabolism. Endocrinology and Metabolism. 2015;30(3):235.
  43. Gonzalez-Gil AM, Elizondo-Montemayor L. The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and Modulation of Inflammation for Energy Substrate Redistribution and Fat Mass Loss: A Review. Nutrients. 2020 Jun 26;12(6):1899.
  44. Letukienė A, Hendrixson V, Ginevičienė V. Current knowledge and scientific trends in myokines and exercise research in the context of obesity. Frontiers in Medicine. 2024 Sep 23;11.
  45. Liu H, Li S, Zhang X, Long W, Liao H, Lu L, et al. Association of Insulin Resistance, Sarcopenia, and Risk of Cardiovascular Disease: Findings From the China Health and Retirement Longitudinal Study. JMIR Aging [Internet]. 2025 Dec 31 [cited 2026 Jan 5];8:e80115–5. Available from: https://aging.jmir.org/2025/1/e80115
  46. Aditya John Binu, Kapoor N, Bhattacharya S, Kamal Kishor, Kalra S. Sarcopenic Obesity as a Risk Factor for Cardiovascular Disease: An Underrecognized Clinical Entity. Heart international. 2023 Jan 1;17(2):6–6.
  47. Wang R, Liu J, Fang G, Shi J, Zhang C, Huang Y. Association between visceral adiposity index and cardiovascular disease: A systematic review and meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases [Internet]. 2025 Jul 2;104216. Available from: https://www.sciencedirect.com/science/article/pii/S0939475325003709
  48. Ruiz-Castell M, Samouda H, Bocquet V, Fagherazzi G, Stranges S, Huiart L. Estimated visceral adiposity is associated with risk of cardiometabolic conditions in a population based study. Scientific Reports. 2021 Apr 27;11(1).
  49. Du Y, Oh C, No J. Associations between Sarcopenia and Metabolic Risk Factors: A Systematic Review and Meta-Analysis. Journal of Obesity & Metabolic Syndrome. 2018 Sep 30;27(3):175–85.
  50. Xin Y, Qian X, Yang Y. Associations between sarcopenic obesity and the risk of cardiovascular-kidney-metabolic syndrome progression: insights from the China health and retirement longitudinal study. Diabetology & Metabolic Syndrome [Internet]. 2025 Dec 29 [cited 2026 Jan 5];17(1):460–0. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12752421/
  51. Tompa R. Massive biomolecular shifts occur in our 40s and 60s, Stanford Medicine researchers find [Internet]. News Center. 2024. Available from: https://med.stanford.edu/news/all-news/2024/08/massive-biomolecular-shifts-occur-in-our-40s-and-60s–stanford-m.html
  52. Shen X, Wang C, Zhou X, Zhou W, Hornburg D, Wu S, et al. Nonlinear dynamics of multi-omics profiles during human aging. Nature Aging [Internet]. 2024 Aug 14;1–16. Available from: https://www.nature.com/articles/s43587-024-00692-2
  53. Devlin H. Scientists find humans age dramatically in two bursts – at 44, then 60 [Internet]. the Guardian. The Guardian; 2024. Available from: https://www.theguardian.com/science/article/2024/aug/14/scientists-find-humans-age-dramatically-in-two-bursts-at-44-then-60-aging-not-slow-and-steady
  54. Humans in. Nonlinear Aging in Humans, with Transition Points of Increased Risk [Internet]. Fight Aging! 2024 [cited 2026 Jan 5]. Available from: https://www.fightaging.org/archives/2024/08/nonlinear-aging-in-humans-with-transition-points-of-increased-risk/
  55. Iqbal SS. Drastic Molecular Shifts in People’s 40s and 60s Might Explain Age-Related Health Changes [Internet]. Scientific American. Scientific American; 2024. Available from: https://www.scientificamerican.com/article/drastic-molecular-shifts-in-peoples-40s-and-60s-might-explain-age-related/
  56. Aging spurts stem from molecular changes [Internet]. Uclahealth.org. UCLA Health; 2024. Available from: https://www.uclahealth.org/news/article/aging-spurts-stem-molecular-changes
  57. Austin D. Your body ages rapidly in two “bursts,” at 44 and 60. Here’s how to prepare. [Internet]. Science. 2024. Available from: https://www.nationalgeographic.com/science/article/human-body-two-rapid-aging-bursts
  58. Antal BB, van Nieuwenhuizen H, Chesebro AG, Strey HH, Jones DT, Clarke K, et al. Brain aging shows nonlinear transitions, suggesting a midlife “critical window” for metabolic intervention. Proceedings of the National Academy of Sciences. 2025 Mar 3;122(10).
  59. Belfield AE, Wilkinson TJ, Henson J, Sargeant JA, Breen L, Hall AP, et al. Sarcopenia prevalence using handgrip strength or chair stand performance in adults living with type 2 diabetes mellitus. Age and Ageing [Internet]. 2024 May 1 [cited 2025 May 20];53(5). Available from: https://academic.oup.com/ageing/article/53/5/afae090/7665134
  60. Lim WS, Cheong CY, Lim JP, Tan MMY, Chia JQ, Malik NA, et al. Singapore clinical practice guidelines for sarcopenia: Screening, diagnosis, management and prevention. Journal of Frailty & Aging. 2022;11(4).
  61. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: Revised European Consensus on Definition and Diagnosis. Age and Ageing [Internet]. 2019 Jan 1;48(1):16–31. Available from: https://pubmed.ncbi.nlm.nih.gov/30312372/
  62. Arnal-Gómez A, Àngels M, Jose Francisco Tomas, Tortosa-Chuliá MA, Mercè Balasch-Bernat, Sentandreu-Mañó T, et al. Using the Updated EWGSOP2 Definition in Diagnosing Sarcopenia in Spanish Older Adults: Clinical Approach. 2021 Mar 2;10(5):1018–8.
  63. Li Y, Wang X, Ya S, Huang Jiaoling, Hua N. The optimal cut‐off value of five‐time chair stand test for assessing sarcopenia among Chinese community‐dwelling older adults. Journal of cachexia, sarcopenia and muscle. 2024 Feb 11;
  64. Núñez-Cortés R, Andersen LL, Cruz-Montecinos C, Polo-López A, Rubén López-Bueno, Calatayud J. Five-repetition chair-stand test vs. handgrip strength: Which better predicts mortality risk? a follow-up study in 43,605 middle-aged and older adults. Brazilian Journal of Physical Therapy. 2025 Sep 24;29(6):101529–9.
  65. Merchant RA, Chan YH, Hui RJY, Lim JY, Kwek SC, Seetharaman SK, et al. Possible Sarcopenia and Impact of Dual-Task Exercise on Gait Speed, Handgrip Strength, Falls, and Perceived Health. Frontiers in Medicine. 2021 Apr 16;8.
  66. Stuck AK, Mäder NC, Bertschi D, Limacher A, Kressig RW. Performance of the EWGSOP2 Cut-Points of Low Grip Strength for Identifying Sarcopenia and Frailty Phenotype: A Cross-Sectional Study in Older Inpatients. International Journal of Environmental Research and Public Health. 2021 Mar 28;18(7):3498.
  67. Spexoto MCB, Ramírez PC, de Oliveira Máximo R, Steptoe A, de Oliveira C, Alexandre T da S. European Working Group on Sarcopenia in Older People 2010 (EWGSOP1) and 2019 (EWGSOP2) criteria or slowness: which is the best predictor of mortality risk in older adults? Age and Ageing [Internet]. 2022 Jul 1 [cited 2022 Oct 23];51(7). Available from: https://academic.oup.com/ageing/article/51/7/afac164/6649128
  68. Paluch AE, Gabriel KP, Fulton JE, Lewis CE, Schreiner PJ, Sternfeld B, et al. Steps per Day and All-Cause Mortality in Middle-aged Adults in the Coronary Artery Risk Development in Young Adults Study. JAMA Network Open [Internet]. 2021 Sep 3;4(9):e2124516. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2783711
  69. Inoue K, Tsugawa Y, Mayeda ER, Ritz B. Association of Daily Step Patterns With Mortality in US Adults. JAMA Network Open [Internet]. 2023 Mar 28;6(3):e235174. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802810?resultClick=1
  70. Higher daily step count linked with lower all-cause mortality [Internet]. National Institute on Aging. Available from: https://www.nia.nih.gov/news/higher-daily-step-count-linked-lower-all-cause-mortality
  71. Mehranghiz Ebrahimi-Mamaghani, Saghafi-Asl M, Saeed Pirouzpanah, Akbar Aliasgharzadeh, Soudabeh Aliashrafi, Niloufar Rezayi, et al. Association of Insulin Resistance with Lipid Profile, Metabolic Syndrome, and Hormonal Aberrations in Overweight or Obese Women with Polycystic Ovary Syndrome. Journal of Health, Population, and Nutrition [Internet]. 2015 Mar;33(1):157. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4438659/
  72. Kavanagh K, Espeland MA, Sutton-Tyrrell K, Barinas-Mitchell E, Khoudary SRE, Wildman RP. Liver fat and SHBG affect insulin resistance in midlife women: The Study of Women’s Health Across the Nation (SWAN). Obesity. 2013 May;21(5):1031–8.
  73. Liu C, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database of Systematic Reviews [Internet]. 2009 Jul 8;3(3). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4324332/
  74. Higher daily step count linked with lower all-cause mortality [Internet]. National Institute on Aging. Available from: https://www.nia.nih.gov/news/higher-daily-step-count-linked-lower-all-cause-mortality
  75. Hurst C, Robinson SM, Witham MD, Dodds RM, Granic A, Buckland C, et al. Resistance exercise as a treatment for sarcopenia: prescription and delivery. Age and Ageing. 2022 Feb;51(2).
  76. O’Bryan SJ, Giuliano C, Woessner MN, Vogrin S, Smith C, Duque G, et al. Progressive Resistance Training for Concomitant Increases in Muscle Strength and Bone Mineral Density in Older Adults: A Systematic Review and Meta-Analysis. Sports Medicine. 2022 May 24;52(8).
  77. American College of Sports Medicine. Progression models in resistance training for healthy adults. Medicine & Science in Sports & Exercise [Internet]. 2009 Mar;41(3):687–708. Available from: https://pubmed.ncbi.nlm.nih.gov/19204579
  78. Yan R, Chen Y, Zhang R, He J, Lin W, Sun J, et al. Optimal resistance training prescriptions to improve muscle strength, physical function, and muscle mass in older adults diagnosed with sarcopenia: a systematic review and meta-analysis. Aging Clinical and Experimental Research [Internet]. 2025 Nov 10;37(1):320–0. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12602684
  79. Wu W, Chen F, Ma H, Lu J, Zhang Y, Zhou H, et al. Dietary protein requirements of older adults with sarcopenia determined by the indicator amino acid oxidation technology. Frontiers in Nutrition. 2025 Feb 28;12.
  80. Yanai H. Nutrition for Sarcopenia. Journal of Clinical Medicine Research [Internet]. 2026 [cited 2026 Jan 5];7(12):926–31. Available from: https://www.jocmr.org/index.php/JOCMR/article/view/2361/1290
  81. Ishaq I, Noreen S, Aja PM, Ayomide Victor Atoki. Role of protein intake in maintaining muscle mass composition among elderly females suffering from sarcopenia. Frontiers in Nutrition. 2025 May 12;12.
  82. Sahu S, Gautam RK. Determinants of body composition among peri-menopausal women of Bilaspur district, Chhattisgarh, India. BMC Public Health. 2025 Jan 6;25(1).
  83. Messier V, Rabasa-Lhoret R, Barbat-Artigas S, Elisha B, Karelis AD, Aubertin-Leheudre M. Menopause and sarcopenia: A potential role for sex hormones. Maturitas. 2011 Apr;68(4):331–6.
  84. Buckinx F, Aubertin-Leheudre M. Sarcopenia in Menopausal Women: Current Perspectives. International Journal of Women’s Health [Internet]. 2022 Jun;Volume 14(1):805–19. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9235827/
  85. Garaulet M, Pérez-Llamas F, Baraza JC, Garcia-Prieto MD, Fardy PS, Tébar FJ, et al. Body fat distribution in pre-and post-menopausal women: metabolic and anthropometric variables. The Journal of Nutrition, Health & Aging [Internet]. 2002;6(2):123–6. Available from: https://pubmed.ncbi.nlm.nih.gov/12166365/
  86. Zhang Z, He Z, Yang H, Li D, Duan P, Wei X. The Accumulation of Visceral Fat in Postmenopausal Women: The Combined Impact of Prenatal Genetics, Epigenetics, and Fat Depot Heterogeneity—A Descriptive Review. Clinical and Experimental Obstetrics & Gynecology. 2025 Feb 18;52(2).
  87. Cho EJ, Choi Y, Jung SJ, Kwak HB. Role of exercise in estrogen deficiency-induced sarcopenia. Journal of Exercise Rehabilitation. 2022 Feb 24;18(1):2–9.
  88. Juppi H, Sipilä S, Fachada V, Hyvärinen M, Cronin N, Aukee P, et al. Total and regional body adiposity increases during menopause—evidence from a follow‐up study. Aging Cell. 2022 May 4;
  89. Lohman T, Going S, Hall M, Ritenbaugh C, Bare L, Hill A, et al. Effects of resistance training on regional and total bone mineral density in premenopausal women: A randomized prospective study. Journal of Bone and Mineral Research [Internet]. 2009 Dec 3;10(7):1015–24. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jbmr.5650100705
  90. Whitman PW, Alexander CJ, Kaluta L, Burt LA, Gabel L. Does exercising during peri- or early post-menopause prevent bone and muscle loss: A systematic review. PubMed. 2025 Sep 16;117650–0.
  91. Sipilä S, Törmäkangas T, Sillanpää E, Aukee P, Kujala UM, Kovanen V, et al. Muscle and bone mass in middle‐aged women: role of menopausal status and physical activity. Journal of Cachexia, Sarcopenia and Muscle. 2020 Feb 3;11(3):698–709.
  92. Bailey C A., Brooke-Wavell K. Exercise for optimising peak bone mass in women. Proceedings of the Nutrition Society. 2008 Jan 30;67(1):9–18.
  93. Liang M, Quezada L, Lau J, Sökmen B, Spalding T. Effect of short-term upper-body resistance training on muscular strength, bone metabolic markers, and BMD in premenopausal women. Open Access Journal of Sports Medicine. 2012 Nov;201.
  94. Panagiotou G, Brage S. Advancing Precision Diagnosis of Sarcopenic Obesity Through Digital Technologies, Wearables and Omics Data. Life [Internet]. 2025 Dec 13 [cited 2026 Jan 5];15(12):1911. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12735172/
  95. Imani M, Borda MG, Vogrin S, Meijering E, Aarsland D, Duque G. Using Deep Learning to Perform Automatic Quantitative Measurement of Masseter and Tongue Muscles in Persons With Dementia: Cross-Sectional Study. JMIR Aging. 2025 Mar 19;8:e63686–6.
  96. Dlima SD, Shevade S, Menezes SR, Ganju A. Digital Phenotyping in Health Using Machine Learning Approaches: A Scoping Review (Preprint). JMIR Bioinformatics and Biotechnology. 2022 May 16;
  97. Zhou Z, Huang Y, Wang J, Su H, Tang H, Wang Y. A novel digital biomarker of sarcopenia in frail elderly: New combination of gait parameters under dual-task walking. Frontiers in aging neuroscience. 2023 Feb 20;15.
  98. Luo X, Ding H, Broyles A, Warden SJ, Moorthi RN, Imel EA. Using machine learning to detect sarcopenia from electronic health records. Digital health. 2023 Jan 1;9.
  99. Rozynek M, Kucybała I, Urbanik A, Wojciechowski W. Use of artificial intelligence in the imaging of sarcopenia: A narrative review of current status and perspectives. Nutrition. 2021 Sep;89:111227.
  100. Pimentel MM, Dos Santos WHB, Rodrigues EK, Gomes Fernandes SG, de Carvalho PF, Fernandes AT do NSF, et al. Monitoring sarcopenia with wearable devices: a systematic review protocol. BMJ open [Internet]. 2023 Spring;13(6):e070507. Available from: https://pubmed.ncbi.nlm.nih.gov/37344114/
  101. Song K, Park HY, Choi S, Song S, Rim H, Yoon MJ, et al. Sarcopenia Diagnostic Technique Based on Artificial Intelligence Using Bio-signal of Neuromuscular System: A Proof-of-Concept Study. Brain & Neurorehabilitation [Internet]. 2024 Jan 1 [cited 2026 Jan 5];17(2):e12–2. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11300961/
  102. Sun Y, Chen J, Ji M, Li X. Wearable Technologies for Health Promotion and Disease Prevention in Older Adults: Systematic Scoping Review and Evidence Map. Journal of Medical Internet Research [Internet]. 2025 Jun 24;27:e69077–7. Available from: https://www.jmir.org/2025/1/e69077
  103. Evolve: Menopause & CardioMetabolic Clinic [Internet]. Evolve: Menopause & CardioMetabolic Clinic. 2025. Available from: https://www.evolvelifeclinic.com/news/how-continuous-glucose-monitoring-cgm-personalized-nutrition-improve-weight-loss-and-metabolic-health
  104. Fetter DS, Dharmar M, Lawry-Hall S, Pressman J, Chapman J, Scherr RE. The Influence of Gain-Framed and Loss-Framed Health Messages on Nutrition and Physical Activity Knowledge. Global Pediatric Health. 2019 Jan;6:2333794X1985740.
  105. Smith JF. Global study: In public health messaging, negative framing triggers anxiety — not better outcomes [Internet]. www.hks.harvard.edu. 2022. Available from: https://www.hks.harvard.edu/faculty-research/policy-topics/health/global-study-public-health-messaging-negative-framing
  106. Ainiwaer A, Zhang S, Ainiwaer X, Ma F. Effects of message framing on cancer prevention and detection behaviors, intentions and attitudes: Systematic Review and Meta-Analysis (Preprint). Journal of Medical Internet Research. 2021 Feb 1;23(9).
  107. Lim MSC, Molenaar A, Brennan L, Reid M, McCaffrey T. Young adults’ use of different social media platforms for health information: Insights from web-based conversations. Journal of Medical Internet Research. 2022;24(1).
  108. Jafar Z. Social media for public health: Reaping the benefits, mitigating the harms. Health promotion perspectives [Internet]. 2023 Jul 10;13(2):105–12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439458/
  109. Picazo-Sánchez L, Domínguez-Martín R, García-Marín D. Health Promotion on Instagram: Descriptive–Correlational Study and Predictive Factors of Influencers’ Content. International Journal of Environmental Research and Public Health. 2022 Nov 28;19(23):15817.
  110. Rothman AJ, Martino SC, Bedell BT, Detweiler JB, Salovey P. The Systematic Influence of Gain-and Loss-Framed Messages on Interest in and Use of Different Types of Health Behavior. Personality and Social Psychology Bulletin. 1999 Nov;25(11):1355–69.

‌